Patents by Inventor Ning Shao

Ning Shao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240183067
    Abstract: MPCVD device comprises deposition platform, substrate platform, lifting platform, microwave quartz window, upper cover plate, baseplate, pressure sensors, composite windows, thickness measuring device, visual device, temperature measuring device, plasma diagnostic device, vacuum sealing ring and microwave shielding sealing ring. Reaction cavity is formed by upper cover plate and baseplate, and inlet hole is arranged on top of upper cover plate, while exhaust hole is arranged on baseplate; microwave quartz window is annular shaped and arranged between deposition platform and baseplate, and reaction cavity is isolated from air outside by microwave quartz window; lifting platform is provided with vacuum channel and cooling channel therein; vacuum cavity, which is communicated with vacuum channel, is formed by lower surface of substrate platform and upper surface of lifting platform; and pressure sensor for monitoring gas pressure is arranged in vacuum cavity.
    Type: Application
    Filed: March 30, 2023
    Publication date: June 6, 2024
    Inventors: Xiaolei Wu, Ning Yan, Shuai Xu, Yanjun Zhao, Junyong Shao, Wentao Zhou, Jiong Zhao, Bolun Cao, Hui Liu, Hongxing Pan
  • Patent number: 11976058
    Abstract: The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: May 7, 2024
    Assignee: BIOARDIS LLC
    Inventors: Ding Wang, Ning Shao, Hongbin Yuan, Frank Kayser
  • Patent number: 11919918
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 5, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Kai Liu, Yeming Wang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao
  • Patent number: 11905274
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 20, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Yeming Wang, Huai Huang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao, Zhenguang Zou
  • Publication number: 20230192699
    Abstract: A compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI, or a pharmaceutically acceptable salt thereof. The structure of Formula I is: wherein R1 is a halogen; n is 0, 1, or 2; X1, X2, X3, X4, X5 and X6 are each independently C or N; R2 is absent or O; and R3 is absent or —CN.
    Type: Application
    Filed: March 26, 2021
    Publication date: June 22, 2023
    Applicant: GRITSCIENCE BIOPHARMACEUTICALS CO., LTD.
    Inventors: Enxing ZHOU, Yuan LIU, Hanping WANG, Jing WANG, Ning SHAO, Guanglong WU
  • Publication number: 20230106958
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.
    Type: Application
    Filed: May 25, 2022
    Publication date: April 6, 2023
    Inventors: Yanping ZHAO, Hongjun WANG, Yeming WANG, Xiang LI, Yuanyuan JIANG, Huai HUANG, Fajie LI, Liying ZHOU, Ning SHAO, Fengping XIAO, Zhenguang ZOU
  • Publication number: 20220389039
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Application
    Filed: May 27, 2022
    Publication date: December 8, 2022
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Xiang LI, Yuanyuan JIANG, Kai LIU, Yeming WANG, Liying ZHOU, Yanan LIU, Ning SHAO, Fengping XIAO
  • Patent number: 11453690
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 27, 2022
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Yeming Wang, Xiang Li, Yuanyuan Jiang, Huai Huang, Fajie Li, Liying Zhou, Ning Shao, Fengping Xiao, Zhenguang Zou
  • Patent number: 11414444
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 16, 2022
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Kai Liu, Yeming Wang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao
  • Publication number: 20220169634
    Abstract: The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 2, 2022
    Inventors: Ding WANG, Ning SHAO, Hongbin YUAN, Frank KAYSER
  • Patent number: 11279697
    Abstract: An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising same in preparing a therapeutic agent, specifically an FGFR4 tyrosine kinase inhibitor, and in preparing a medicament for treating and/or preventing neoplastic and inflammatory diseases. The substituents of formula (I) are same as defined in the description.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: March 22, 2022
    Assignee: BIOARDIS LLC
    Inventors: Ning Shao, Ding Wang, Hongbin Yuan, Frank Kayser
  • Publication number: 20210395231
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.
    Type: Application
    Filed: February 22, 2019
    Publication date: December 23, 2021
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Xiang LI, Yuanyuan JIANG, Yeming WANG, Huai HUANG, Liying ZHOU, Yanan LIU, Ning SHAO, Fengping XIAO, Zhenguang ZOU
  • Publication number: 20210179648
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Application
    Filed: October 31, 2018
    Publication date: June 17, 2021
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Xiang LI, Yuanyuan JIANG, Kai LIU, Yeming WANG, Liying ZHOU, Yanan LIU, Ning SHAO, Fengping XIAO
  • Patent number: 10961570
    Abstract: A high-throughput and rapid nucleic acids detection method based on capillary microarrays comprises the steps that firstly, microarray containing a number of hydrophilic and vertical micro-channels is fabricated by capillary assembling, casting and machining, and the outer surface of the capillary array is coated with super-hydrophobic Ultra-Ever Dry paint; secondly, different primer sets are individually loaded into the micro-channels and air-dried to adhere them on the inner surface, and then the microarray is anchored into a reaction tube; thirdly, the reaction mixture is introduced into every microchannel at once through capillary force by a special designed sample-loading adaptor, and then the amplification reaction is performed in the temperature control device; and finally, the fluorescence can either be measured continually during the reaction for real-time detection or be recorded once in the end for endpoint detection. Moreover, the products can also be recovered for other use later.
    Type: Grant
    Filed: April 2, 2016
    Date of Patent: March 30, 2021
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Shengce Tao, Litao Yang, Ning Shao, Jiaying Hu, Jianwei Chen, Dabing Zhang
  • Publication number: 20210054007
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: February 25, 2021
    Inventors: Yanping ZHAO, Hongjun WANG, Yeming WANG, Xiang LI, Yuanyuan JIANG, Huai HUANG, Fajie LI, Liying ZHOU, Ning SHAO, Fengping XIAO, Zhenguang ZOU
  • Publication number: 20200262827
    Abstract: An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising same in preparing a therapeutic agent, specifically an FGFR4 tyrosine kinase inhibitor, and in preparing a medicament for treating and/or preventing neoplastic and inflammatory diseases. The substituents of formula (I) are same as defined in the description.
    Type: Application
    Filed: September 4, 2018
    Publication date: August 20, 2020
    Applicant: BIOARDIS LLC
    Inventors: Ning SHAO, Ding WANG, Hongbin YUAN, Frank KAYSER
  • Publication number: 20190240646
    Abstract: The present invention discloses a mesoporous manganese ferrite Fenton-like catalyst and preparation method and application thereof and pertains to the field of preparation of Fenton-like catalysts. The present invention uses KIT-6 as a hard template agent to synthesize mesoporous manganese ferrite catalyst. The prepared mesoporous manganese ferrite and hydrogen peroxide constitute a Fenton-like system oxidation wastewater treatment system to carry out efficient removal and mineralization of organic pollutants in wastewater. The preparation method of the present invention is simple and efficient. The prepared Fenton-like catalyst has a mesoporous structure and a relatively large specific surface area.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 8, 2019
    Inventors: Jinnan WANG, Suqian XU, Ning SHAO
  • Publication number: 20190119722
    Abstract: The present invention discloses a high-throughput and rapid nucleic acids detection method based on capillary microarrays, and belongs to the technical field of biomedicine.
    Type: Application
    Filed: April 2, 2016
    Publication date: April 25, 2019
    Inventors: Shengce Tao, Litao Yang, Ning Shao, Jiaying Hu, Jianwei Chen, Dabing Zhang
  • Patent number: 10239863
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ning Shao, Scott D. Edmondson, Santhosh Neelamkavil, Zhuyan Guo, Eric Mertz, Yi Zang, Jiafang He
  • Publication number: 20180179180
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: October 20, 2017
    Publication date: June 28, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ning Shao, Scott D. Edmondson, Santhosh Neelamkavil, Zhuyan Guo, Eric Mertz, Yi Zang, Jiafang He